Parameters |  | F value | p value | Post-Hoc (Mean ± SE) |
---|---|---|---|---|
pH | Time | 2.03 | 0.14 | Â |
 | Treatments | 32.02 | < 0.0001 |  |
 | Time:Treatments | 0.58 | 0.86 |  |
 | Post-hoc comparison |  |  | Corexit 9500 ( 8.05 ± 0.04) |
 |  |  |  | oWSF + Corexit 9500 (7.99 ± 0.04) |
 |  |  |  | oWSF + pBMC-BC + Corexit 9500 (8.06 ± 0.04) |
 |  |  |  | oWSF (8.34 ± 0.04) |
 |  |  |  | pBMC-BC (8.54 ± 0.04) |
 |  |  |  | oWSF + pBMC-BC (8.61 ± 0.04) |
 |  |  |  | Control (8.47 ± 0.04) |
DOC | Time | 11.24 | < 0.001 |  |
 | Treatments | 1.51 | 0.21 |  |
 | Time:Treatments | 1.22 | 0.29 |  |
 | Post-hoc comparison |  |  | T0 (3.24 μg/mL ± 0.26) |
 |  |  |  | T1 (4.44 mg/mL ± 0.26) |
 |  |  |  | T2 (4.53 μg/mL ± 0.26) |
Salinity | Time | 78.9 | < 0.0001 |  |
 | Treatments | 2.8 | 0.03 |  |
 | Time:Treatments | 1.6 | 0.11 |  |
 | Post-hoc comparison |  |  | T0 (36.22 mg/L ± 0.07) |
 |  |  |  | T1 (36.17 mg/L ± 0.07) |
 |  |  |  | T2 (37.25 mg/L ± 0.07) |
 |  |  |  | Control (36.70 mg/L ± 0.12) |
 |  |  |  | oWSF (36.42 mg/L ± 0.12) |
 |  |  |  | pBMC-BC (36.74 mg/L ± 0.12) |
 |  |  |  | Corexit 9500 (36.60 mg/L ± 0.12) |
 |  |  |  | oWSF + pBMC-BC (36.20 mg/L ± 0.14) |
 |  |  |  | oWSF + Corexit 9500 (36.38 mg/L ± 0.12) |
 |  |  |  | pBMC-BC + Corexit 9500 (36.85 mg/L ± 0.12) |
 |  |  |  | oWSF + pBMC-BC + Corexit 9500 (36.47 mg/L ± 0.12) |
Ammonium | Time | 14.86 | < 0.0001 |  |
 | Treatments | 1.33 | 0.28 |  |
 | Time:Treatments | 1.07 | 0.41 |  |
 | Post-hoc comparison |  |  | T0 (28.10 μg/L ± 19.22) |
 |  |  |  | T1 (160.09 μg/L ± 19.22) |
 |  |  |  | T2 (99.83 μg/L ± 19.22) |
Nitrate | Time | 6.88 | 0.002 | Â |
 | Treatments | 0.35 | 0.92 |  |
 | Time:Treatments | 0.72 | 0.74 |  |
 | Post-hoc comparison |  |  | T0 (6.56 μg/L ± 10.76) |
 |  |  |  | T1 (58.11 μg/L ± 10.76) |
 |  |  |  | T2 (34.65 μg/L ± 10.76) |
Phosphate | Time | 20.21 | < 0.0001 |  |
 | Treatments | 5.59 | < 0.001 |  |
 | Time:Treatments | 3.37 | < 0.001 |  |
 | Post-hoc comparison |  |  | Control in T0 (18.65 μg/L ± 23.19), T1 (61.80 μg/L ± 23.19) and T2 (33.82 μg/L ± 23.19) |
 |  |  |  | oWSF in T0 (13.96 μg/L ± 23.19), T1 (25.24 μg/L ± 23.19) and T2 (17.26 μg/L ± 23.19) |
 |  |  |  | pBMC-BC in T0 (5.97 μg/L ± 23.19), T1 (51.55 μg/L ± 23.19) and T2 (70.67 μg/L ± 23.19) |
 |  |  |  | Corexit 9500 in T0 (3.22 μg/L ± 23.19), T1 (234.27 μg/L ± 23.19) and T2 (136.47 μg/L ± 23.19) |
 |  |  |  | oWSF + pBMC-BC in T0 (6.76 μg/L ± 23.19), T1 (56.20 μg/L ± 23.19) and T2 (97.50 μg/L ± 23.19) |
 |  |  |  | oWSF + Corexit 9500 in T0 (0 μg/L ± 23.19), T1 (83.35 μg/L ± 23.19) and T2 (53.00 μg/L ± 23.19) |
 |  |  |  | pBMC-BC + Corexit 9500 in T0 (3.22 μg/L ± 23.19), T1 (3.77 μg/L ± 23.19) and T2 (109.82 μg/L ± 23.19) |
 |  |  |  | oWSF + pBMC-BC + Corexit 9500 in T0 (3.77 μg/L ± 23.19), T1 (78.75 μg/L ± 23.19) and T2 (34.20 μg/L ± 23.19) |
PAH | Time | 7.86 | 0.001 | Â |
 | Treatments | 20.86 | < 0.0001 |  |
 | Time:Treatments | 3.31 | 0.001 |  |
 | Post-hoc comparison |  |  | Control in T0 (1.63 μg/L ± 467.05), T1 (0.48 μg/L ± 467.05) and T2 (0.58 μg/L ± 467.05) |
 |  |  |  | oWSF in T0 (4.36 μg/L ± 467.05), T1 (0.61 μg/L ± 467.05) and T2 (1.26 μg/L ± 467.05) |
 |  |  |  | pBMC-BC in T0 (0.08 μg/L ± 467.05), T1 (0.06 μg/L ± 467.05) and T2 (0.10 μg/L ± 467.05) |
 |  |  |  | Corexit 9500 in T0 (17.72 μg/L ± 467.05), T1 (5.99 μg/L ± 467.05) and T2 (4.99 μg/L ± 467.05) |
 |  |  |  | oWSF + pBMC-BC in T0 (3.39 μg/L ± 539.30), T1 (0.03 μg/L ± 539.30) and T2 (0.14 μg/L ± 539.30) |
 |  |  |  | oWSF + Corexit 9500 in T0 (803.19 μg/L ± 467.05), T1 (4665.46 μg/L ± 467.05) and T2 (2711.75 μg/L ± 467.05) |
 |  |  |  | pBMC-BC + Corexit 9500 in T0 (8.60 μg/L ± 467.05), T1 (9.39 μg/L ± 467.05) and T2 (3.94 μg/L ± 467.05) |
 |  |  |  | oWSF + pBMC-BC + Corexit 9500 in T0 (1162.94 μg/L ± 467.05), T1 (4559.76 μg/L ± 467.05) and T2 (2165.55 μg/L ± 467.05) |
N-alkanes | Time | 4.84 | 0.013 | Â |
 | Treatments | 9.98 | < 0.0001 |  |
 | Time:Treatments | 2.21 | 0.022 |  |
 | Post-hoc comparison |  |  | Control in T0 (1.63 μg/L ± 467.05), T1 (0.48 μg/L ± 467.05) and T2 (0.58 μg/L ± 467.05) |
 |  |  |  | oWSF in T0 (4.36 μg/L ± 467.05), T1 (0.61 μg/L ± 467.05) and T2 (1.26 μg/L ± 467.05) |
 |  |  |  | pBMC-BC in T0 (0.08 μg/L ± 467.05), T1 (0.06 μg/L ± 467.05) and T2 (0.10 μg/L ± 467.05) |
 |  |  |  | Corexit 9500 in T0 (17.72 μg/L ± 467.05), T1 (5.99 μg/L ± 467.05) and T2 (4.99 μg/L ± 467.05) |
 |  |  |  | oWSF + pBMC-BC in T0 (3.39 μg/L ± 539.30), T1 (0.03 μg/L ± 539.30) and T2 (0.14 μg/L ± 539.30) |
 |  |  |  | oWSF + Corexit 9500 in T0 (803.19 μg/L ± 467.05), T1 (4665.46 μg/L ± 467.05) and T2 (2711.75 μg/L ± 467.05) |
 |  |  |  | pBMC-BC + Corexit 9500 in T0 (8.60 μg/L ± 467.05), T1 (9.39 μg/L ± 467.05) and T2 (3.94 μg/L ± 467.05) |
 |  |  |  | oWSF + pBMC-BC + Corexit 9500 in T0 (1162.94 μg/L ± 467.05), T1 (4559.76 μg/L ± 467.05) and T2 (2165.55 μg/L ± 467.05) |